Hong Kong Urological Association–Hong Kong Society of Uro‐Oncology consensus statements on the management of advanced prostate cancer—2019 Updates

Background To update the Hong Kong Urological Association–Hong Kong Society of Uro‐Oncology consensus statements on the management of advanced prostate cancer, the same panelists as in the previous consensus panel held a series of meetings to discuss updated clinical evidence and experiences. Methods The previous consensus statements were retained, deleted, or revised, and new statements were added. At the final meeting, all statements were reviewed and amended as appropriate, followed by panel voting. Results There were significant changes and additions to the previous consensus statements, primarily driven by the advances in androgen receptor signaling inhibitors, treatment sequencing in metastatic castration‐resistant prostate cancer, and increasing recognition of oligometastatic prostate cancer since the introduction of prostate‐specific membrane antigen positron emission tomography. In this update, a total of 59 consensus statements were accepted and established. Conclusions The consensus panel updated consensus statements on the management of advanced prostate cancer, aiming to allow physicians in the region to keep abreast of the recent evidence on optimal clinical practices.